←Back to Expert Scholars
Translational Medicine / 转化医学Breast Cancer, NATALEE Adjuvant Ribociclib
Dennis Slamon
MD, PhD
🏢UCLA🌐USA
Professor and Chief of Hematology-Oncology
125
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Dennis Slamon, already famous for his HER2/trastuzumab discoveries, led the NATALEE trial establishing adjuvant ribociclib benefit in stage II-III HR-positive breast cancer. His leadership has shaped both HER2 and CDK4/6 inhibitor development over three decades.
Share:
🧪Research Fields 研究领域
NATALEE trial
adjuvant ribociclib
HER2 targeting legacy
UCLA breast program
HR-positive early breast
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Dennis Slamon 的研究动态
Follow Dennis Slamon's research updates
留下邮箱，当我们发布与 Dennis Slamon（UCLA）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment